Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study

International Journal of Radiation Oncology Biology Physics

Volumn 95, Issue 5, 2016, Pages 1504-1512

  Wu, Jia ^a   Gensheimer, Michael F ^a   Dong, Xinzhe ^a   Rubin, Daniel L ^a   Napel, Sandy ^a   Diehn, Maximilian ^a,b   Loo, Billy W ^a,b   Li, Ruijiang ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CLUSTERING ALGORITHMS; DISEASES; FORECASTING; HAZARDS; PATIENT MONITORING; PATIENT TREATMENT; PIXELS; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; RISK MANAGEMENT; TUMORS;

FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHIES; HIER-ARCHICAL CLUSTERING; INSTITUTIONAL REVIEW BOARDS; KAPLAN-MEIER ANALYSIS; MAXIMUM STANDARDIZED UPTAKE VALUES; METABOLIC TUMOR VOLUMES; PARTITIONING FRAMEWORKS; STANDARDIZED UPTAKE VALUES;

COMPUTERIZED TOMOGRAPHY;

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INSTITUTIONAL REVIEW; LUNG CANCER; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PET-CT SCANNER; PILOT STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT PLANNING; TUMOR VOLUME; CALIFORNIA; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; IMAGE GUIDED RADIOTHERAPY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREVALENCE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURGICAL MARGIN; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CALIFORNIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MARGINS OF EXCISION; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY, IMAGE-GUIDED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84975517936     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.03.018     Document Type: Article

References (41)

1. 1 Fischer, B., Lassen, U., Mortensen, J., et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 361 (2009), 32–39.
2. 2 Ciernik, I.F., Dizendorf, E., Baumert, B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 57 (2003), 853–863.
3. 3 Ohri, N., Duan, F., Machtay, M., et al. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. J Natl Cancer Inst, 107, 2015.
4. 4 Machtay, M., Duan, F., Siegel, B.A., et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: Results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 31 (2013), 3823–3830.
5. 5 Nair, V.J., MacRae, R., Sirisegaram, A., et al. Pretreatment [F-18]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: Rethinking the role of positron emission tomography in personalizing treatment based on risk status. Int J Radiat Oncol Biol Phys 88 (2014), 312–318.
6. 6 Satoh, Y., Onishi, H., Nambu, A., et al. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: Prognostic value. Radiology 270 (2014), 275–281.
7. 7 Lee, P., Bazan, J.G., Lavori, P.W., et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer 13 (2012), 52–58.
8. 8 Liao, S., Penney, B.C., Wroblewski, K., et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 39 (2012), 27–38.
9. 9 Guerra, J.L.L., Gladish, G., Komaki, R., et al. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer. J Nucl Med 53 (2012), 225–233.
10. 10 van Elmpt, W., Ollers, M., Dingemans, A.M., et al. Response assessment using F-18-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med 53 (2012), 1514–1520.
11. 11 Fried, D.V., Mawlawi, O., Zhang, L., et al. Stage III non-small cell lung cancer: Prognostic value of FDG PET quantitative imaging features combined with clinical prognostic factors. Radiology 278 (2016), 214–222.
12. 12 Coroller, T.P., Grossmann, P., Hou, Y., et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol 114 (2015), 345–350.
13. 13 Aerts, H.J., Velazquez, E.R., Leijenaar, R.T., et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun, 5, 2014, 4006.
14. 14 Hatt, M., Majdoub, M., Vallieres, M., et al. F-18-FDG PET uptake characterization through texture analysis: Investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 56 (2015), 38–44.
15. 15 Fried, D.V., Tucker, S.L., Zhou, S., et al. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 90 (2014), 834–842.
16. 16 Vallieres, M., Freeman, C.R., Skamene, S.R., et al. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol 60 (2015), 5471–5496.
17. 17 Wu, J., Aguilera, T., Shultz, D., et al. Early-stage non-small cell lung cancer: Quantitative imaging characteristics of 18F Fluorodeoxyglucose PET/CT allow prediction of distant metastasis. Radiology, 2016, 151829.
18. 18 Gatenby, R.A., Grove, O., Gillies, R.J., Quantitative imaging in cancer evolution and ecology. Radiology 269 (2013), 8–15.
19. 19 O'Connor, J.P., Rose, C.J., Waterton, J.C., et al. Imaging intratumor heterogeneity: Role in therapy response, resistance, and clinical outcome. Clin Cancer Res 21 (2015), 249–257.
20. 20 Farjam, R., Tsien, C.I., Feng, F.Y., et al. Physiological imaging-defined, response-driven subvolumes of a tumor. Int J Radiat Oncol Biol Phys 85 (2013), 1383–1390.
21. 21 Grove, O., Berglund, A.E., Schabath, M.B., et al. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS One, 10, 2015, e0118261.
22. 22 Klein, S., Staring, M., Murphy, K., et al. Elastix: A toolbox for intensity-based medical image registration. IEEE Trans Med Imaging 29 (2010), 196–205.
23. 23 Kanungo, T., Mount, D.M., Netanyahu, N.S., et al. An efficient k-means clustering algorithm: Analysis and implementation. IEEE T Pattern Anal 24 (2002), 881–892.
24. 24 Johnson, S.C., Hierarchical clustering schemes. Psychometrika 32 (1967), 241–254.
25. 25 Tibshirani, R., Walther, G., Hastie, T., Estimating the number of clusters in a data set via the gap statistic. J R Stat Soc B 63 (2001), 411–423.
26. 26 Fortin, D., Basran, P.S., Berrang, T., et al. Deformable versus rigid registration of PET/CT images for radiation treatment planning of head and neck and lung cancer patients: A retrospective dosimetric comparison. Radiat Oncol, 9, 2014, 50.
27. 27 Kapp, A.V., Tibshirani, R., Are clusters found in one dataset present in another dataset?. Biostatistics 8 (2007), 9–31.
28. 28 Vesselle, H., Schmidt, R.A., Pugsley, J.M., et al. Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6 (2000), 3837–3844.
29. 29 Zegers, C.M., van Elmpt, W., Reymen, B., et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F] HX4 and [18F] FDG-PET/CT imaging. Clin Cancer Res 20 (2014), 6389–6397.
30. 30 Win, T., Miles, K.A., Janes, S.M., et al. Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res 19 (2013), 3591–3599.
31. 31 Cook, G.J., O'Brien, M.E., Siddique, M., et al. Non-small cell lung cancer treated with erlotinib: Heterogeneity of F-FDG uptake at PET—association with treatment response and prognosis. Radiology 276 (2015), 883–893.
32. 32 Cook, G.J., Yip, C., Siddique, M., et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?. J Nucl Med 54 (2013), 19–26.
33. 33 Cui, Y., Tha, K.K., Terasaka, S., et al. Prognostic imaging biomarkers in glioblastoma: Development and independent validation on the basis of multiregion and quantitative analysis of MR images. Radiology 278 (2016), 546–553.
34. 34 El Naqa, I., Grigsby, P., Apte, A., et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 42 (2009), 1162–1171.
35. 35 Wang, P., Popovtzer, A., Eisbruch, A., et al. An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in advanced head-and-neck cancer. Med Phys 39 (2012), 5277–5285.
36. 36 Hatt, M., Le Rest, C.C., Descourt, P., et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys 77 (2010), 301–308.
37. 37 Bradley, J.D., Paulus, R., Komaki, R., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol 16 (2015), 187–199.
38. 38 Nehmeh, S., Erdi, Y., Pan, T., et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 31 (2004), 3179–3186.
39. 39 Toma-Dasu, I., Uhrdin, J., Lazzeroni, M., et al. Evaluating tumor response of non-small cell lung cancer patients with 18 F-fludeoxyglucose positron emission tomography: Potential for treatment individualization. Int J Radiat Oncol Biol Phys 91 (2015), 376–384.
40. 40 Zhang, H., Tan, S., Chen, W., et al. Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18 F-FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol Biol Phys 88 (2014), 195–203.
41. 41 Wu, J., Gong, G., Cui, Y., et al. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy. Journal of Magnetic Resonance Imaging, 2016 in press.